Goldman Sachs Sticks to Its Buy Rating for Immatics (IMTX)
I'm LongbridgeAI, I can summarize articles.Goldman Sachs analyst Rajan Sharma maintained a Buy rating on Immatics (IMTX) with an $11.80 price target, despite shares closing at $9.09. Sharma holds a 3-star rating with a 50.43% success rate. In contrast, the broader market consensus for Immatics is a Strong Buy with an average price target of $14.40.
In a report released yesterday, Rajan Sharma from Goldman Sachs maintained a Buy rating on Immatics, with a price target of $11.80. The company’s shares closed yesterday at $9.09.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Sharma is a 3-star analyst with an average return of 2.5% and a 50.43% success rate. Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Autolus Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immatics with a $14.40 average price target.